Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Go back to Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.70 +0.20 (1.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.50 | 52 Week High | $117.12 | |||
| Open | $14.79 | 52 Week Low | $46.52 | |||
| Day High | $14.84 | P/E | N/A | |||
| Day Low | $14.07 | EPS | $-1.97 | |||
| Volume | 3,378,709 | |||||
